US OptionsDetailed Quotes
XFOR250117P2000
- 1.35
- 0.000.00%
15min DelayTrading Jan 17 16:00 ET
0.00High0.00Low
0.00Open1.35Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-31.05%PremiumJan 17, 2025Expiry Date1.50Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.37Leverage Ratio--Theta--Rho--Eff Leverage--Vega
X4 Pharmaceuticals Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards to...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards to...
62
15
6
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
53
20
11
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
$X4 Pharmaceuticals (XFOR.US)$
I believe this will go up it just needs a little time. I have a position still.
I believe this will go up it just needs a little time. I have a position still.
2
2
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals Inc - to Submit Maa to EMA for Mavorixafor in Whim Syndrome
X4 Pharmaceuticals Inc - to Submit Maa to EMA for Mavorixafor in Whim Syndrome
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones
X4 Pharmaceuticals Inc - to Receive €28.5 Mln Upfront, up to €226 Mln in Milestones
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
$X4 Pharmaceuticals (XFOR.US)$ Reuters· 1 min ago
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
1
$X4 Pharmaceuticals (XFOR.US)$
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Monday, 13th January at 7:35 am
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
Upfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's gl...
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Monday, 13th January at 7:35 am
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
Upfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's gl...
1
No comment yet
WilsonVJR : Hi Jaguar, may I know whats PR refer to?
Jaguar8 OP WilsonVJR : press release
Jaguar8 OP WilsonVJR : read the NOTE before all the stocks
Juz give me my money : Thank You for your hardwork
JET_WoW : no longer interested in ptle?
View more comments...